The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2

This publication has 41 references indexed in Scilit:

• Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer
  Cancer, 1985
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
  The Journal of Experimental Medicine, 1984
• Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.
  The Journal of Experimental Medicine, 1983
• Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells
  The Journal of Experimental Medicine, 1983
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982
• Cell-mediated suppression of tumor immunity has a non-specific component. I. Evidence from transplantation tests
  International Journal of Cancer, 1981
• T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.
  The Journal of Experimental Medicine, 1980
• Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population.
  The Journal of Experimental Medicine, 1978
• Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows
  Science, 1976
• MODELS FOR SYNGENEIC ADOPTIVE CHEMOIMMUNOTHERAPY OF MURINE LEUKEMIAS*
  Annals of the New York Academy of Sciences, 1976